1. Ministry of Health, Labor and Welfare, Scientific Research Grant 2017, Study of type 1 diabetes mellitus to estimate actual condition, objective diagnostic criteria, and severity assessment based on daily activity and social activity. Type 1 diabetes mellitus in which insulin secretion is completely lost. 2018. Accessed July 18, 2019. http://dmic.ncgm.go.jp/content/type1_insulin_20180817.pdf
Google Scholar2. International Diabetic Federation . Diabetes Atlas Eighth Edition. 2017. Accessed July 18, 2019. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html
Google Scholar3. American Diabetes Association. Position statement. 9 . Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42:S90-S102.
Google Scholar4. Davidson, PC, Hebblewhite, HR, Steed, RD, Bode, BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract. 2008;14:1095-1101.
Google Scholar | Crossref | Medline5. Lebovitz, H, Sherr, J, Tamborlane, W, Bode, B. Insulin pump therapy in therapy for diabetes mellitus and related disorders (ed Lebovitz, H ). 5th ed. American Diabetes Association; 2009:322-331.
Google Scholar6. Wolpert, H, Wolpert, H. Smart pumping for people with diabetes (ed H Wolpert). American Diabetes Association; 2002.
Google Scholar7. Kuroda, A, Kaneto, H, Yasuda, T, et al. Basal insulin requirement is ~30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care. 2011;34:1089-1090.
Google Scholar | Crossref | Medline8. King, AB. How much do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoring. Endocr Pract. 2010;16:428-432.
Google Scholar | Crossref | Medline | ISI9. Purnell, JQ, Brafett, BH, Zinman, B, et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Care. 2017;40:1756-1762.
Google Scholar | Crossref | Medline10. Tascini, G, Berioli, MG, Cerquiglini, L, et al. Carbohydrate counting in children and adolescents with type 1 diabetes. Nutrients. 2018;10:109.
Google Scholar | Crossref11. Japan Diabetes Clinical Data Management Study Group . 2007. Accessed July 18, 2019. http://jddm.jp/data/index-2017.html
Google Scholar12. Boeder, S, Edelman, SV. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: a review of randomized controlled trials. Diabetes Obes Metab. 2019;21:62-77.
Google Scholar | Crossref | Medline13. Henry, RR, Thakkar, P, Tong, C, Polidori, D, Alba, M. Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38:2258-2265.
Google Scholar | Crossref | Medline | ISI14. Dandona, P, Mathieu, C, Phillip, M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicenter, double-blind, phase 3, randomized controlled trial. Lancet Diabetes Endocrinol. 2017;5:864-876.
Google Scholar | Crossref | Medline15. Mathieu, C, Dandona, P, Gillard, P, et al., on behalf of the DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41:1938-1946.
Google Scholar | Crossref | Medline16. Pieber, TR, Famulla, S, Eilbracht, J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17:928-935.
Google Scholar | Crossref | Medline | ISI17. Rosenstock, J, Marquard, J, Laffel, LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41:2560-2569.
Google Scholar | Crossref | Medline18. Buse, JB, Garg, SK, Rosenstock, J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41:1970-1980.
Google Scholar | Crossref | Medline19. Danne, T , et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41:1981-1990.
Google Scholar | Crossref | Medline20. Garg, SK, Henry, RR, Banks, P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377:2337-2348.
Google Scholar | Crossref | Medline21. Blau, JE, Rother, KI, Beitelshees, AL. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet diabetes Endocrinol. 2019;7:949-958.
Google Scholar | Crossref | Medline22. Patoulias, D, Imprialos, K, Stavropoulos, K, Athyros, V, Doumas, M. SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature. Curr Clin Pharmacol. 2018;13:261-272.
Google Scholar | Crossref | Medline23. Nauck, MA, Del Prato, S, Meier, JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015-2022.
Google Scholar | Crossref | Medline | ISI24. Wanner, C, Heerspink, HJL, Zinman, B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol. 2018;29:2755-2769.
Google Scholar | Crossref | Medline25. Lehecka, KE, Renukuntla, VS, Heptulla, RA. Insight into hypoglycemia in pediatric type 1 diabetes mellitus. Int J Pediatr Endocrinol. 2012;2012:19.
Google Scholar | Crossref | Medline26. Kovatchev, B, Cobelli, C. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care. 2016;39:502-510.
Google Scholar | Crossref | Medline | ISI27. Schade, DS, Eaton, RP. Metabolic and clinical significance of ketosis. Spec Top in Endocrinol Metab. 1982;4:1-27.
Google Scholar | Medline28. Wiggam, MI, O’Kane, MJ, Harper, R, et al. Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. Diabetes Care. 1997;20:1347-1352.
Google Scholar | Crossref | Medline29. Urakami, T, Kuwabara, R, Habu, M, Okuno, M, Suzuki, J, Takahashi, S. Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes. J Diabetes Investig. 2015;6:87-90.
Google Scholar | Crossref | Medline30. Musso, G, Roberto Gambino, R, Cassader, M, Paschetta, E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019; 365:l1328.
Google Scholar | Crossref | Medline31. Hampp, C, Swain, RS, Horgan, C, et al. Use of sodium–glucose cotransporter 2 inhibitors in patients with type 1 diabetes and rates of diabetic ketoacidosis. Diabetes Care. 2020;43:90-97.
Google Scholar | Crossref | Medline32. Benoit, SR, Zhang, Y, Geiss, LS, Gregg, EW, Albright, A. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality – United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2018;67:362-365.
Google Scholar | Crossref | Medline